Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company has closed a growth capital funding round of $168 million.

Caris Life Sciences announced plans to go public, testing a technology initial public offering market that’s been frozen over for most of the year.. The Irving-based AI diagnostic company said ...

Before its two most recent rounds, Caris snagged $150 million in debt financing in October 2018 from Sixth Street, which also contributed an additional $75 million in debt financing to the 2020 round.

IRVING, Texas, April 7, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company has closed ...